Search clinical trials for: advanced high grade serous ovarian carcinoma

Total 66670 results

Alexandria University

Recruiting

Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Ovarian Epithelial Cancer

Egypt
A2A Pharmaceuticals Inc.

Recruiting

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Triple Negative Breast Cancer | Endometrial Cancer | High Grade Serous Ovarian Cancer

United States
Sun Yat-sen University

Not yet recruiting

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer | High Grade Serous Adenocarcinoma of Ovary | High Grade Endometrioid Ovarian Cancer | Fallopian-tube Cancer

China
Volastra Therapeutics, Inc.

Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Gastric Adenocarcinoma | Uterine Carcinosarcoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Transitional Cell Carcinoma of Bladder | Colorectal Adenocarcinoma | Gastroesophageal Junction... and other conditions

United States
Centre Hospitalier Universitaire Vaudois

Not yet recruiting

PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma (CHUV-OVACURE)

Ovarian Carcinoma
OncoC4, Inc.
Merck Sharp & Dohme LLC; GOG Foundation

Recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial) (NHIPEC)

Neoadjuvant Chemotherapy | Hyperthermic Intraperitoneal Chemotherapy

China
Seagen Inc.

Recruiting

A Study of SGN-B7H4V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Adenoid Cystic Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Endometrial Neoplasms | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Carcinoma | HER2 Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms

United States, Spain, Canada, United Kingdom, Germany, Italy
M.D. Anderson Cancer Center

Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Chondrosarcoma | Advanced Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous... and other conditions

United States
Seagen Inc.

Recruiting

A Study of SGN-B6A in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Non-Small Cell Lung | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | HER2 Negative Breast Neoplasms and other conditions

United States, Spain, United Kingdom, France, Switzerland
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Stage II Fallopian Tube Cancer AJCC v8 | Stage II Ovarian... and other conditions

United States, Canada, Korea, Republic of, Puerto Rico, Ireland
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Advanced Pancreatic Adenocarcinoma | Platinum-Resistant... and other conditions

United States
Seagen Inc.

Terminated

A Study of SGN-STNV in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Colorectal Neoplasms | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Pseudomyxoma Peritonei | Carcinoma, Non-Small Cell Lung | Gastroesophageal Junction Carcinoma | HER2 Negative Breast Neoplasms | Exocrine Pancreatic Adenocarcinoma | Appendiceal...

United States, United Kingdom, Canada, Spain, France, Italy
TCR2 Therapeutics
Bristol-Myers Squibb

Active, not recruiting

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Cholangiocarcinoma | Non Small Cell Lung Cancer Metastatic | Mesotheliomas Pleural | Mesothelioma Peritoneum | Mesothelioma; Pleura | Cholangiocarcinoma Recurrent | High Grade Ovarian Serous Adenocarcinoma

United States, Canada
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

Ovarian Cancer | High Grade Ovarian Serous

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Seagen Inc.

Terminated

A Study of SGN-ALPV in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Testicular Neoplasms | Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Gastroesophageal Junction Carcinoma

United States, Canada, Spain, Sweden, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrolling by invitation

New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer

Ovarian Cancer | Neoadjuvant Chemotherapy | Prognostic Cancer Model

China
Volastra Therapeutics, Inc.
Amgen

Completed

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada, Italy, Australia, Japan, Belgium, Spain
zr Pharma & GmbH
Foundation Medicine

Completed

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United Kingdom, United States, Israel, Spain, Italy, Czechia, Canada, Hungary, Poland, Russian Federation, Brazil, Ukraine
Imperial College London
North Eastern German Society of Gynaecological Oncology; Takeda Pharmaceuticals...

Active, not recruiting

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (DICE)

Ovarian Neoplasms | Fallopian Tube Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma

United Kingdom, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 and other conditions

United States
MaxCyte, Inc.
CTI Clinical Trial and Consulting Services

Terminated

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Fallopian Tube Adenocarcinoma | Peritoneal Mesothelioma | Primary Peritoneal Carcinoma | Adenocarcinoma of the Ovary

United States
Curis, Inc.

Completed

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

High-grade Serous Ovarian Cancer | Solid Tumors | Triple-Negative Breast Cancer | NUT Midline Carcinoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Recruiting

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging (MR-O-MICS)

High Grade Serous Ovarian Cancer

France
Volastra Therapeutics, Inc.

Recruiting

A Study of Sovilnesib in Subjects With Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary | Chromosomal Instability

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma

United States
Sunnybrook Health Sciences Centre
GlaxoSmithKline

Recruiting

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Ovarian Cancer | Stage IV Ovarian Cancer | High Grade Ovarian Serous Adenocarcinoma | Stage III Ovarian Cancer

Canada
University Health Network, Toronto

Not yet recruiting

68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study (FAST HOC)

High Grade Serous Ovarian Cancer (HGSOC)
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
Mayo Clinic

Recruiting

A Study of FRaDCs for Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditions

United States
OncoC4, Inc.
Avance Clinical; OncoC4 AU Pty Ltd

Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Fallopian Tube Cancer | Non Small Cell Lung Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Primary Peritoneal... and other conditions

Australia
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Neoplasms, Ovarian

Australia, United States, Korea, Republic of, Chile, Belgium, Italy, Spain, Israel, Japan
ProfoundBio US Co.

Recruiting

PRO1184 for Advanced Solid Tumors (PRO1184-001)

Ovarian Cancer | Fallopian Tube Cancer | Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Primary Peritoneal Carcinoma | Breast Adenocarcinoma | High Grade Epithelial Ovarian Cancer | Hormone Receptor-positive/Her2 Negative Breast Cancer

United States, China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
Liz-Anne Lewsley
Ovarian Cancer Action

Recruiting

Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma (BriTROC-2)

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma | Primary Peritoneal Carcinoma | Carcinosarcoma, Ovarian

United Kingdom
ImmunoGen, Inc.

Recruiting

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
University of Oklahoma
Verastem, Inc.

Recruiting

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK)

Cervical Cancer | Solid Tumor | Endometrioid Cancer | Mucinous Ovarian Cancer | High Grade Serous Ovarian Cancer

United States
North Eastern German Society of Gynaecological...
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Not yet recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Clear Cell Carcinoma
Sunnybrook Health Sciences Centre
Centre hospitalier de l'Université de Montréal (CHUM); Exactis Innovation; Princess...

Recruiting

Combination of Olaparib and Navitoclax in Women With HGSC and TNBC

Ovarian Cancer | Triple Negative Breast Cancer | High Grade Serous Carcinoma

Canada
Scancell Ltd

Recruiting

Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY)

Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Renal Cell Cancer | High Grade Ovarian Serous Adenocarcinoma

United Kingdom

Search clinical trials for: advanced high grade serous ovarian carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations